M
Morphogenesis
Biotech & Life Sciences · United States · Founded 1995
Developing novel cell and gene therapies MoreLess
Morphogenesis, Inc. is a clinical-stage biotechnology company focused on developing novel cell and gene therapies to treat chronic diseases, particularly cancer. The company operates in the biopharmaceutical market, targeting both healthcare providers and patients seeking advanced treatment options. Morphogenesis' core business model revolves around the research, development, and clinical trials of its proprietary immunotherapies, which aim to engage the body's innate intelligence to fight diseases. Revenue is primarily generated through partnerships, grants, and future commercialization of its therapies. Currently, the company is conducting a first-in-human clinical study for cutaneous cancers and expanding the use of its intralesional cancer vaccine for advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.
Keywords: immunotherapy, chronic disease, cancer treatment, cell therapy, gene therapy, clinical trials, biotechnology, biopharmaceutical, cancer vaccine, healthcare innovation.
Company overview
Morphogenesis company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 1995
- Headquarters
- United States
- Employees
- 32
- Open positions
- None listed
- Dealroom signal
- 56.1
- Investment activity
- 1 companies · latest May 2023
- Capital deployed
- —
- Preferred round
- MERGER
Valuation & funding
Morphogenesis funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| MERGER✓Other financing | May 2023 | $0 | — | Cohbar | ↗ |
| EARLY VC✓Equity / VC | Jul 2022 | $9.1M | $36M | Undisclosed | ↗ |
| SERIES A✓Equity / VC | May 2018 | $16M | $64M | Kiran Patel | — |
| SPINOUT✓Other financing | Jan 1995 | $0 | — | AdventHealth | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 32 |
| 2025 | 23 |
| 2024 | 14 |
| 2023 | 14 |
Growth signals
Morphogenesis website traffic
Latest recorded traffic for Morphogenesis is 200 monthly website visits, down 70.1% over the last three months. Morphogenesis's team grew 39.1% over the past year.
Comparisons
Morphogenesis compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Morphogenesis investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Morphogenesis's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Morphogenesis has talent and traffic
team presence
In the news
Latest news about Morphogenesis
Recent press, funding announcements, and product moves mentioning Morphogenesis — open to read from the original sources.
Market sentiment
What the market is saying about Morphogenesis
An AI-synthesized read of the highest-engagement posts about Morphogenesis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Morphogenesis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.